
News • Russian biotechnology
Biocad prepares to enter the European market
The Russian biotechnology company Biocad plans to enter the European market with oncological and autoimmune medicines. So far, there are seven molecules in the European portfolio of Biocad. The biosimilar products could be used in treatment of melanoma, breast, stomach, kidney and lung cancer, rheumatoid arthritis, psoriasis and multiple sclerosis.
























